Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alumis Inc. - Common Stock (NQ: ALMS )

11.32 +0.09 (+0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 71,372
Open 11.11
Bid (Size) 11.32 (19)
Ask (Size) 11.36 (5)
Prev. Close 11.23
Today's Range 11.11 - 11.80
52wk Range 9.540 - 13.53
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
Via Benzinga

Performance

YTD
-14.89%
-14.89%
1 Month
+5.99%
+5.99%
3 Month
-7.97%
-7.97%
6 Month
-14.89%
-14.89%
1 Year
-14.89%
-14.89%

More News

Read More
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Alumis to Participate in Upcoming September Investor Conferences
From Alumis Inc.
Via GlobeNewswire
ALMS Stock Earnings: Alumis Reported Results for Q2 2024
Via InvestorPlace
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
From Alumis Inc.
Via GlobeNewswire
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
From Alumis Inc.
Via GlobeNewswire
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
Via Benzinga
Ardent Health Slips After Downsized IPO
Via Talk Markets
Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.